Review of Therapeutic Approach in Common Hormone Disorders

Albatool Almukairish

Department of Clinical Biochemistry, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.

Aliaa Sabban

Department of Clinical Biochemistry, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.

Khalid Bakheit *

Department of Clinical Biochemistry, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.

*Author to whom correspondence should be addressed.


Abstract

Hormones have a critical role in regulating a number of body functions, including mood, metabolism, growth and development, and reproductive health. This article covers common hormone disorders, as well as their causes, symptoms, complications, and available treatments. Common treatment modalities for hormone problems include medication, lifestyle modifications, surgery, complementary therapies, and routine monitoring. The course of treatment may also be accompanied by possible negative effects, such as cancer risk, hormone overcorrection, and interactions with other medications or medical conditions. Regular hormone level and symptom evaluations by healthcare professionals are necessary to provide individual treatment plans that lower the risk of complications while achieving the desired therapeutic goals.

Keywords: Hormone disorders, therapeutic approach, hormone replacement


How to Cite

Almukairish , A., Sabban, A., & Bakheit , K. (2024). Review of Therapeutic Approach in Common Hormone Disorders. Asian Journal of Research and Reports in Endocrinology, 7(1), 1–10. Retrieved from https://journalajrre.com/index.php/AJRRE/article/view/85

Downloads

Download data is not yet available.

References

Mentis AF, Chrousos GP. BMC Endocrine Disorders’ collection of articles on Reducing inequalities in the Management of Endocrine Disorders. BMC Endocrine Disorders. 2022;22(1):1-2.

Goljan EF. Endocrine Disorders. In: Rapid Review Pathology Revised Reprint. Elsevier. 2011;475–514.

What are the symptoms of endocrine disorders? Far North Surgery; 2022.

Available:https://www.farnorthsurgery.com/blog/symptoms-of-endocrine-disorders

Chopra R, Chander A, Jacob JJ. The eye as a window to rare endocrine disorders. Indian Journal of Endocrinology and Metabolism. 2012;16(3):331-8.

Goubar T, Torpy DJ, McGrath S, Rushworth RL. Prehospital management of acute Addison disease: Audit of patients attending a referral hospital in a regional area. J Endocr Soc. 2019;3(12):2194–203.

Available:http://dx.doi.org/10.1210/js.2019-00263

Addison’s disease Mayo Clinic; 2022. Available:https://www.mayoclinic.org/diseases-conditions/addisons-disease/symptom s-causes/syc-20350293

Crafa A, Calogero AE, Cannarella R, Mongioi’ LM, Condorelli RA, Greco EA, et al. The burden of hormonal disorders: A worldwide overview with a particular look in Italy. Front Endocrinol (Lausanne). 2021; 12:694325. Available:http://dx.doi.org/10.3389/fendo.2021.694325

Clayton RN. Cardiovascular complications of Cushings Syndrome: impact on morbidity and mortality. Journal of Neuroendocrinology. 2022;34(8).

Krystallenia I Alexandraki, Ashley B Grossman. Therapeutic strategies for the treatment of severe cushing's syndrome. Drugs. 2016;76(4):447-58. DOI: 10.1007/s40265-016-0539-6

Claahsen-van der Grinten HL, Speiser PW, Ahmed SF, Arlt W, Auchus RJ, Falhammar H, Flück CE, Guasti L, Huebner A, Kortmann BB, Krone N. Congenital adrenal hyperplasia—current insights in pathophysiology, diagnostics, and management. Endocrine reviews. 2022;43 (1):91-159.

Reisch N. Review of health problems in adult patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Experimental and Clinical Endocrinology & Diabetes. 2019;127 (02/03):171-7.

Bartalena L, Chiovato L, Vitti P. Management of hyperthyroidism due to Graves’ disease: Frequently asked questions and answers (if any). Journal of Endocrinological Investigation. 2016;39: 1105-14.

Bobanga ID, McHenry CR. Treatment of patients with Graves' disease and the appropriate extent of thyroidectomy. Best Practice & Research Clinical Endocrinology & Metabolism. 2019 ;33(4):101319.

Hashimoto’s disease. National Institute of Diabetes and Digestive and Kidney Diseases. NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases; 2022.

Available:https://www.niddk.nih.gov/health-information/endocrine-diseases/hashimotos-disease

Adelman DT, Liebert KJ, Nachtigall LB, Lamerson M, Bakker B. Acromegaly: The disease, its impact on patients, and managing the burden of long-term treatment. International Journal of General Medicine. 2013;31-8.

Rolla M, Jawiarczyk-Przybyłowska A, Halupczok-Żyła J, Kałużny M, Konopka BM, Błoniecka I, Zieliński G, Bolanowski M. Complications and Comorbidities of Acromegaly—Retrospective Study in Polish Center. Frontiers in Endocrinology. 2021;12:642131.

Noda H, Guo J, Khatri A, Dean T, Reyes M, Armanini M, Brooks DJ, Martins JS, Schipani E, Bouxsein ML, Demay MB. An Inverse Agonist Ligand of the PTH Receptor Partially Rescues Skeletal Defects in a Mouse Model of Jansen's Metaphyseal Chondrodysplasia. Journal of Bone and Mineral Research. 2020;35 (3):540-9.

Nampoothiri S, Fernández-Rebollo E, Yesodharan D, Gardella TJ, Rush ET, Langman CB, Jüppner H. Jansen metaphyseal chondrodysplasia due to heterozygous H223R-PTH1R mutations with or without overt hypercalcemia. The Journal of Clinical Endocrinology & Metabolism. 2016;101(11):4283-9.

Glovaci D, Fan W, Wong ND. Epidemiology of diabetes mellitus and cardiovascular disease. Current Cardiology Reports. 2019;21:1-8.

Verhulst MJ, Loos BG, Gerdes VE, Teeuw WJ. Evaluating all potential oral complications of diabetes mellitus. Frontiers in endocrinology. 2019;10:56.

Clarke BL, Brown EM, Collins MT, et al. Epidemiology and diagnosis of hypoparathyroidism. J Clin Endocrinol Metab. 2016;101(6):2284–2299.

Siraj N, Hakami Y, Khan A. Medical hypoparathyroidism. Endocrinol Metab Clin North Am. 2018;47(4):797–808.

Matfin G. Therapeutic advances in endocrinology and metabolism: new crossroads in innovation, research, and clinical practice. Therapeutic Advances in Endocrinology and Metabolism. 2010;1(1): 3-4.

de Carvalho GA, Paz-Filho G, Junior CM, Graf H. Management of endocrine disease: Pitfalls on the replacement therapy for primary and central hypothyroidism in adults. European Journal of Endocrinology. 2018;178(6):R231-44.

Munir S, Rodriguez BS, Waseem M, Haddad LM. Addison Disease (Nursing). In StatPearls. StatPearls Publishing; 2022.

Langer RD, Hodis HN, Lobo RA, Allison MA. Hormone replacement therapy–where are we now? Climacteric. 2021;24(1):3-10.

Brown T, Anderson W, Keys W. Acromegaly and Dentistry: A Review. Dental Update. 2022;49(3):214-8.

Ragnarsson O. Cushing's syndrome–Disease monitoring: Recurrence, surveillance with biomarkers or imaging studies. Best Practice & Research Clinical Endocrinology & Metabolism. 2020;34(2): 101382.

Mallappa A, Merke DP. Management challenges and therapeutic advances in congenital adrenal hyperplasia. Nature Reviews Endocrinology. 2022;18(6):337-52.

Well E. Bioidentical hormones. Adv Nurse Pract. 2009;17(9):37–8, 40–1.

Available:https://my.clevelandclinic.org/health/articles/15660-bioidentical-hormones

Beavers KM, Greene KA, Elaine WY. Management of endocrine disease: bone complications of bariatric surgery: Updates on sleeve gastrectomy, fractures, and interventions. European Journal of Endocrinology. 2020;183(5):R119-32.